Oruka Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay

Oruka Therapeutics, Inc.

Elected Carl Dambkowski (26,047,914 for) and Peter Harwin (25,935,823 for) as Class I directors.
Ratified PricewaterhouseCoopers as independent auditor for FY 2025 (26,781,030 for, 1,848 against).
Non-binding advisory vote approved named executive officer compensation (25,824,834 for, 88,740 against).
Non-binding vote favored annual frequency for future say-on-pay; board adopted annual frequency.
All proposals passed; broker non-votes of 732,854 on director and compensation proposals.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.